This Article Full Text Full Text (PDF) All Versions of this Article: 40/1/28    most recent 01.HYP.0000022606.52221.2Fv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Naruse, M. Articles by Takano, K. Search for Related Content PubMed PubMed Citation Articles by Naruse, M. Articles by Takano, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Hazardous Substances DB DEXAMETHASONE SPIRONOLACTONE Related Collections Other hypertension

(Hypertension. 2002;40:28.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Aldosterone Breakthrough During Angiotensin II Receptor Antagonist Therapy in Stroke-Prone Spontaneously Hypertensive Rats

Mitsuhide Naruse; Akiyo Tanabe; Atsuhisa Sato; Sachiko Takagi; Ken Tsuchiya; Toshihiro Imaki; Kazue Takano

From the Department of Medicine, Institute of Clinical Endocrinology (M.N., A.T., S.T., K.Ta.) and Kidney Center (K.Ts.), Tokyo Women’s Medical University, Tokyo; the Department of Internal Medicine, Mito Red Cross Hospital (A.S.), Mito, Ibaragi; and Institute of Gerontology, Nippon Medical School (T.I.), Kawasaki, Kanagawa, Japan.

Correspondence to Mitsuhide Naruse, MD, Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. E-mail mtsnaruse{at}endm.twmu.ac.jp

Aldosterone breakthrough during ACE inhibitor therapy has been reported. This study investigates changes in plasma aldosterone concentration (PAC) and its mechanism and effects on target organ damage during long-term angiotensin II type 1 (AT1) receptor antagonist (AT1A) therapy in hypertensive rats. An AT1A (candesartan, 1 mg/kg per day PO) was administered in stroke-prone spontaneously hypertensive rats from 4 weeks of age for 34 weeks. PAC was significantly decreased during the first 4 weeks but showed aldosterone breakthrough after 8 weeks of AT1A administration. Plasma angiotensin II concentration was significantly elevated, whereas no change was seen in plasma ACTH or serum potassium. The mechanism(s) of aldosterone breakthrough were investigated by giving high doses of candesartan (3 mg/kg per day PO), dexamethasone (200 µg/kg per day IP), or the AT2 antagonist (PD123319, 10 mg/kg per day SC) during the last week of the 24-week AT1A treatment period. Dexamethasone and AT2 antagonist but not high-dose AT1A produced a significant decrease in PAC, with a larger decrease produced by the AT2 antagonist. To clarify the effects of the residual aldosterone, effects of coadministration of low-dose spironolactone (10 mg/kg per day SC), an aldosterone antagonist, on left ventricular hypertrophy and expression of brain natriuretic peptide mRNA were determined. Low-dose spironolactone further improved left ventricular hypertrophy and brain natriuretic peptide mRNA expression despite no additional depressor effect. These results suggest that aldosterone breakthrough occurs during long-term AT1A therapy, mainly by an AT2-dependent mechanism. Residual aldosterone may attenuate the cardioprotective effects of AT1A.

Key Words: aldosterone • angiotensin II • rats, inbred SHR • receptors, angiotensin II

This article has been cited by other articles:

				P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179. [Abstract] [Full Text] [PDF]

				K. Graf, T. Hucko, and P. Stawowy Cardiac Benefits of Mineralocorticoid Receptor Inhibition in Renal Failure Hypertension, August 1, 2008; 52(2): 209 - 210. [Full Text] [PDF]

				H. Otani, F. Otsuka, K. Inagaki, J. Suzuki, T. Miyoshi, Y. Kano, J. Goto, T. Ogura, and H. Makino Aldosterone Breakthrough Caused by Chronic Blockage of Angiotensin II Type 1 Receptors in Human Adrenocortical Cells: Possible Involvement of Bone Morphogenetic Protein-6 Actions Endocrinology, June 1, 2008; 149(6): 2816 - 2825. [Abstract] [Full Text] [PDF]

				S. Kasama, T. Toyama, H. Sumino, N. Matsumoto, Y. Sato, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Additive Effects of Spironolactone and Candesartan on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients with Congestive Heart Failure J. Nucl. Med., December 1, 2007; 48(12): 1993 - 2000. [Abstract] [Full Text] [PDF]

				L. Segall, A. Covic, and D. J. A. Goldsmith Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol. Dial. Transplant., September 1, 2007; 22(9): 2435 - 2439. [Full Text] [PDF]

				A. K.Y. Chan, J. E. Sanderson, T. Wang, W. Lam, G. Yip, M. Wang, Y.-Y. Lam, Y. Zhang, L. Yeung, E. B. Wu, et al. Aldosterone Receptor Antagonism Induces Reverse Remodeling When Added to Angiotensin Receptor Blockade in Chronic Heart Failure J. Am. Coll. Cardiol., August 14, 2007; 50(7): 591 - 596. [Abstract] [Full Text] [PDF]

				K. Skov, H. Eiskjaer, H. E. Hansen, J. K. Madsen, S. Kvist, and M. J. Mulvany Treatment of Young Subjects at High Familial Risk of Future Hypertension With an Angiotensin-Receptor Blocker Hypertension, July 1, 2007; 50(1): 89 - 95. [Abstract] [Full Text] [PDF]

				L. C. Rump Secondary rise of albuminuria under AT1-receptor blockade--what is the potential role of aldosterone escape? Nephrol. Dial. Transplant., January 1, 2007; 22(1): 5 - 8. [Full Text] [PDF]

				T. R. Marcy and T. L. Ripley Aldosterone antagonists in the treatment of heart failure Am. J. Health Syst. Pharm., January 1, 2006; 63(1): 49 - 58. [Abstract] [Full Text] [PDF]

				J. Katada, T. Meguro, H. Saito, A. Ohashi, T. Anzai, S. Ogawa, and T. Yoshikawa Persistent Cardiac Aldosterone Synthesis in Angiotensin II Type 1A Receptor-Knockout Mice After Myocardial Infarction Circulation, May 3, 2005; 111(17): 2157 - 2164. [Abstract] [Full Text] [PDF]

				A. D Struthers and T. M MacDonald Review of aldosterone- and angiotensin II-induced target organ damage and prevention Cardiovasc Res, March 1, 2004; 61(4): 663 - 670. [Abstract] [Full Text] [PDF]

				S. Arima, K. Kohagura, H.-L. Xu, A. Sugawara, A. Uruno, F. Satoh, K. Takeuchi, and S. Ito Endothelium-Derived Nitric Oxide Modulates Vascular Action of Aldosterone in Renal Arteriole Hypertension, February 1, 2004; 43(2): 352 - 357. [Abstract] [Full Text] [PDF]